Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
69.72 USD +3.55% Intraday chart for Intra-Cellular Therapies, Inc. +3.73% -2.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Intra-Cellular Therapies CFO Hineline Retiring, Promotes Halstead to President MT
Intra-Cellular Therapies, Inc. Announces Executive Changes CI
Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer CI
Intra-Cellular Therapies Insider Sold Shares Worth $1,458,650, According to a Recent SEC Filing MT
Intra-Cellular Therapies Insider Sold Shares Worth $1,808,253, According to a Recent SEC Filing MT
Needham Adjusts Intra-Cellular Therapies Price Target to $82 From $72, Maintains Buy Rating MT
Transcript : Intra-Cellular Therapies, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Intra-Cellular Therapies Q4 Loss Narrows, Revenue Increases MT
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q4 Revenue $132.1M MT
Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024 CI
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Mizuho Increases PT on Intra-Cellular Therapies to $82 From $76 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating MT
Intra-Cellular Therapies Insider Sold Shares Worth $2,272,694, According to a Recent SEC Filing MT
Intra-cellular Therapies Insider Sold Shares Worth $787,719, According to a Recent SEC Filing MT
Intra-cellular Therapies Insider Sold Shares Worth $796,367, According to a Recent SEC Filing MT
Intra-cellular Therapies Insider Sold Shares Worth $414,355, According to a Recent SEC Filing MT
Intra-cellular Therapies Insider Sold Shares Worth $12,680,892, According to a Recent SEC Filing MT
Goldman Sachs Raises Intra-Cellular Therapies' Price Target to $64 From $58, Keeps Neutral Rating MT
Intra-cellular Therapies Insider Sold Shares Worth $3,341,699, According to a Recent SEC Filing MT
Transcript : Intra-Cellular Therapies, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 08:15 AM
Baird Initiates Intra-Cellular Therapies With Outperform Rating, Price Target is $83 MT
RBC Boosts Price Target on Intra-Cellular Therapies to $86 From $76, Keeps Outperform Rating MT
Intra-cellular Therapies Insider Sold Shares Worth $1,382,030, According to a Recent SEC Filing MT
TD Cowen Starts Coverage on Intra-Cellular Therapies with Outperform Rating, $75 Price Target MT
Chart Intra-Cellular Therapies, Inc.
More charts
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellularsignaling mechanisms within the central nervous system (CNS). The Company's product CAPLYTA is a treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled bipolar depression studies, which evaluated the effects of CAPLYTA on depression in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study 404) and as adjunctive therapy with lithium or valproate (Study 402).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
69.72 USD
Average target price
83.1 USD
Spread / Average Target
+19.20%
Consensus
  1. Stock
  2. Equities
  3. Stock Intra-Cellular Therapies, Inc. - Nasdaq
  4. News Intra-Cellular Therapies, Inc.
  5. Jefferies Adjusts Price Target for Intra-Cellular Therapies to $85 From $70, Maintains Buy Rating